Novabay Pharmaceuticals (NBY) |
|
0.7249 -0.005 (-0.7%)
|
10-23 23:16 |
|
Open: |
0.74 |
Pre. Close: |
0.73 |
|
High:
|
0.74 |
Low:
|
0.71 |
|
Volume:
|
602,905 |
Market Cap:
|
32M |
|
|
|
|
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. The company is headquartered in Emeryville, California and currently employs 70 full-time employees. The firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The firm's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.741 - 0.746 |
0.746 - 0.749 |
|
Low:
|
0.699 - 0.705 |
0.705 - 0.709 |
|
Close:
|
0.712 - 0.721 |
0.721 - 0.727 |
|
Technical analysis |
as of: 2020-10-23 4:47:00 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.94 One year: 1.02 |
| Support: |
Support1: 0.69 Support2: 0.57 |
| Resistance: |
Resistance1: 0.80 Resistance2: 0.87 |
| Pivot: |
0.75 |
| Moving Average: |
MA(5): 0.73 MA(20): 0.75 
MA(100): 0.97 MA(250): 0.80 |
| MACD: |
MACD(12,26): -0.02 Signal(9): -0.02 |
| Stochastic oscillator: |
%K(14,3): 12.15 %D(3): 11.78 |
| RSI: |
RSI(14): 40.63 |
| 52-week: |
High: 1.94 Low: 0.24 Change(%): 29.4 |
| Average Vol(K): |
3-Month: 268100 10-Days: 94807 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.NBY has closed above bottom band by 22.8%. Bollinger Bands are 68.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to NBY's normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 15 Oct 2020
Why Will Spark The Next Run With NovaBay Pharmaceuticals, Inc. (NBY) Shares? - Invest Million
Mon, 12 Oct 2020
NovaBay Pharmaceuticals Regains Compliance with NYSE American Listing Standards - Business Wire
Sun, 11 Oct 2020
Should You Observe this stock? NovaBay Pharmaceuticals, (NBY) - Armenian Reporter
Fri, 09 Oct 2020
NovaBay Pharmaceuticals Inc. (NBY) last month volatility was 8.12%: Don’t Ignore this Blaring Warning Signal - News Daemon
Fri, 09 Oct 2020
Why NovaBay Pharmaceuticals Inc. (NBY) Is in Such Horrid Condition - The News Heater
Fri, 09 Oct 2020
NovaBay® Pharmaceuticals Inc. (NYSEAMERICAN:NBY) Expands Consumer Marketing Efforts For Avenova - BP Journal
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
42 |
| Shares Float (M) |
33 |
|
% Held by Insiders
|
41.27 |
|
% Held by Institutions
|
6.53 |
|
Shares Short (K)
|
515 |
|
Shares Short P. Month (K)
|
546 |
Stock Financials |
|
EPS
|
-0.361 |
|
EPS Est This Year
|
-0.470 |
|
EPS Est Next Year
|
-0.090 |
|
Book Value (p.s.)
|
0.030 |
|
Profit Margin
|
-97.79 |
|
Operating Margin
|
-68.19 |
|
Return on Assets (ttm)
|
-34.0 |
|
Return on Equity (ttm)
|
-681.2 |
|
Qtrly Rev. Growth
|
122.7 |
|
Gross Profit (p.s.)
|
0.116 |
|
Sales Per Share
|
0.221 |
|
EBITDA (p.s.)
|
-0.149 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-5 |
|
Levered Free Cash Flow (M)
|
-2 |
Stock Valuations |
|
PE Ratio
|
-2.01 |
|
PEG Ratio
|
|
|
Price to Book value
|
24.16 |
|
Price to Sales
|
3.27 |
|
Price to Cash Flow
|
-6.26 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
